相关临床试验
489
68 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1906
进行中（未招募）
41
8.4%
已完成
264
54.0%
Enrolling By Invitation
8
1.6%
尚未招募
19
3.9%
招募中
89
18.2%
终止
22
4.5%
Unknown
16
3.3%
撤回
30
6.1%
暂无批准数据
- A 21-year-old man, dubbed the "Kansas City Patient," has achieved sustained HIV remission 17 months after stopping antiretroviral therapy following a CCR5-delta32 stem cell transplant for acute myeloid leukemia. - He is the youngest person ever to be potentially cured of HIV through stem cell transplantation, with undetectable plasma HIV RNA, intact proviral DNA, and replication-competent virus. - The Essen Patient was also reported at AIDS 2026, becoming the first person with hepatitis B co-infection to achieve HIV remission after a similar transplant procedure. - Experts caution that stem cell transplantation remains a high-risk, non-scalable procedure reserved for life-threatening cancers, though each case provides insights for broader HIV cure research.
- A 42-day spaceflight on the ISS led to reduced fertility in female mice, with fewer pups born compared to ground controls. - Offspring of space-flown dams showed altered body weights, behavioral changes, and reduced fecundity over a nine-month period. - Transgenerational effects were observed in grandpups, including altered responses to a high-fat diet, suggesting heritable changes. - Researchers hypothesize mitochondrial dysfunction and epigenetic modifications may underlie the observed reproductive and metabolic changes.
- The University of Kansas Health System, University of Kansas Medical Center, Children's Mercy, and BAMF Health announced plans to establish one of the nation's first fully integrated theranostics platforms serving both adult and pediatric patients. - The collaboration will create a state-of-the-art facility housing radiopharmaceutical production, molecular imaging, radiopharmaceutical therapy, and radioligand clinical trials in one location. - Children's Mercy represents one of the first pediatric health systems to invest early in theranostics technology, ensuring children access to this precision medicine approach. - The platform will expand beyond current applications in metastatic prostate cancer and neuroendocrine cancer to include clinical trials for neurologic conditions such as Alzheimer's disease.
- Medera and University of Kansas Medical Center successfully treated the first patient in the MUSIC-DMD Phase 1b trial, marking the first-in-human gene therapy approach for DMD-associated cardiomyopathy. - The AAV1.SERCA2a gene therapy was delivered via minimally invasive intracoronary infusion, with the patient tolerating the procedure well and being discharged after overnight observation. - The trial addresses a critical unmet need as cardiac complications have become the leading cause of death in DMD patients, affecting nearly all patients by age 18. - The open-label study will enroll up to 12 adult males across low-dose, high-dose, and control groups to evaluate safety and efficacy of the one-time gene therapy treatment.
- The University of Kansas Medical Center received a five-year, $31 million NIH grant to coordinate pediatric clinical trials across 18 rural and underserved sites, marking the largest award in the institution's history. - In partnership with the University of Nebraska Medical Center, KU will serve as the Data Coordinating and Operations Center for the ECHO IDeA States Pediatric Clinical Trials Network, providing biostatistics support and facilitating multi-site study design. - The network focuses on environmental influences affecting child health, including air pollution, family support, stress, sleep habits, and diet, with recent research linking arsenic in drinking water to adverse birth outcomes. - The initiative addresses critical healthcare disparities by providing clinical trial access to children in IDeA states that historically have limited research funding and restricted access to vital clinical trials.
- The NIH-funded MOVE Peds study represents the first large-scale clinical investigation of pediatric facioscapulohumeral muscular dystrophy (FSHD), addressing critical gaps in understanding disease progression in children. - Springbok Analytics is providing AI-powered muscle analysis technology that quantifies both fat infiltration and inflammation markers while minimizing scan time to under 45 minutes—crucial for pediatric patients. - Data from the multi-site study will establish essential natural history metrics, validate outcome measures, and potentially accelerate regulatory pathways for emerging FSHD therapies targeting children.
• A groundbreaking clinical trial, NOURISH, aims to combat food insecurity and malnutrition in blood cancer patients undergoing transplant or cellular therapy through structured food assistance programs. • Cancer patients experiencing malnutrition face increased risks of infection, longer hospital stays, reduced treatment tolerance, and higher mortality rates, according to Dr. Anna Arthur, the study's primary investigator. • The trial provides patients with bi-weekly food bags containing 2-3 days of balanced nutrition, along with recipes and cooking demonstrations to support optimal nutritional intake during treatment.
• Two leading CAR-T cell therapies, ciltacabtagene autoleucel and idecabtagene vicleucel, demonstrate encouraging results in treating relapsed/refractory multiple myeloma patients in earlier treatment lines. • Clinical data supports the potential benefits of moving CAR-T cell therapy to earlier treatment stages, potentially improving patient outcomes before disease progression becomes more advanced. • Healthcare institutions are developing structured referral processes and treatment protocols to optimize patient selection and timing of CAR-T therapy implementation.
